A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
Clinical trial NCT05979363 · RECRUITING
Trial details
- NCT number
- NCT05979363
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-14
- Primary completion
- 2026-07-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.